Status:
UNKNOWN
Mohs Versus Traditional Surgery - Basal-Cell Carcinomas (BCC)
Lead Sponsor:
Hospital Ambroise Paré Paris
Conditions:
Carcinoma, Basal Cell
Eligibility:
All Genders
18+ years
Brief Summary
Mohs' micrographic surgery (MMS) is a treatment of choice for high recurrence risk basal-cell carcinomas (BCC). Realized under local anaesthesia, it induces very low recurrence rates and spares unnece...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Histologically proved cutaneous BCC
- Categorized as "bad prognostic" according to the 2004 recommendations of ANAES
- morpheaform or ill-limited clinical forms and histologically aggressive forms (morpheaform, micronodular, infiltrating, squamous differentiation) OR
- already recurred BCC (except for superficial BCCs) OR
- nodular BCCs from the high-risk zone (nose and peri-orificial areas of the head) and with diameter larger than 1 cm.
- Life expectancy greater than 3 years according to the investigator's opinion.
- Patient being informed and having signed the consent to participate to the study
Exclusion
- History of X-ray therapy in the territory of the BCC
- Counter-indication to surgery
- Life expectancy \< 3 years
- superficial BCCs, even if recurred
- Patient being unable to attend future follow-up visits
- Patient with severe cognitive impairment
- Patient not affiliated to a social security regimen
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00699829
Start Date
June 1 2008
Last Update
February 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Ambroise Paré
Boulogne, France, 92100